(Q41516656)

2 October 2017

title

Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines (English)

1 reference

2 October 2017

M Petrini

1

1 reference

2 October 2017

L Mattii

2

1 reference

2 October 2017

P Valentini

3

1 reference

2 October 2017

A R Sabbatini

4

1 reference

2 October 2017

B Grassi

5

1 reference

2 October 2017

M Grandi

6

1 reference

2 October 2017

publication date

1 November 1993

1 reference

2 October 2017

1 reference

2 October 2017

volume

67

1 reference

2 October 2017

issue

5

1 reference

2 October 2017

page(s)

227-230

1 reference

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients

2 October 2017

cites work

1 reference

12 December 2020

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

12 December 2020

Linkage between surface immunoglobulin and cytoskeleton of B lymphocytes may involve Gc protein

1 reference

12 December 2020

MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia.

1 reference

12 December 2020

9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance

1 reference

12 December 2020

Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.

1 reference

12 December 2020

Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem.

1 reference

12 December 2020

Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo

1 reference

12 December 2020

Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells

1 reference

12 December 2020

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

1 reference

12 December 2020

Nicardipine as a chemosensitizing agent in two P-glycoprotein-positive leukemic patients

1 reference

12 December 2020

Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype

1 reference

12 December 2020

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

1 reference

12 December 2020

Multidrug resistance and its circumvention

1 reference

12 December 2020

Characterization by somatic cell genetics of a monoclonal antibody to the MDR1 gene product (P-glycoprotein): determination of P-glycoprotein expression in multi-drug-resistant KB and CEM cell variants

1 reference

12 December 2020

High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission.

1 reference

12 December 2020

Expression of p170 protein in multiple myeloma: a clinical study

1 reference

12 December 2020

Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies

1 reference

12 December 2020

P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.

1 reference

12 December 2020

Multidrug resistance: focus in hematology.

1 reference

12 December 2020

Morpholinyl anthracyclines: option for reversal of anthracycline resistance

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01715052

1 reference

2 October 2017

1 reference